Establishment of a HEK293T stable cell line capable of secreting GRP78-specific scFv-targeted nanovesicles

Document Type : Original Research Article

Authors

1 Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

2 Asbestos and Dust Diseases Research Institute (ADDRI), Sydney, NSW, Australia

10.22034/nmrj.2024.01.006

Abstract

Objective(s): Exosomes are nanovesicular vehicles capable of transporting different cargoes. Based on their characteristics, exosomes are proposed as a class of vehicles for targeted delivery of therapeutics. We aimed to establish a HEK293T stable cell line capable of secreting GRP78-specific scFv-targeted exosomes.
Methods: The pLEX-LAMP2b-GRP78 construct was developed by enzymatic replacement of DARPin in pLEX-LAMP2b-DARPin with a GRP78-specific scFv. pLEX-LAMP2b-GRP78 (or TurboGFP as control), psPAX2, and pMD2.G plasmids were co-transfected into HEK293T cells, and produced lentiviruses were harvested. Different multiplicities of infection (MOI; 10, 20, 30, 60, 120, and 240) were used for the transduction of HEK293T to select the most appropriate one as assessed by flow cytometry. Transduced HEK293T cells were subject to puromycin selection and the presence of the scFv was assessed in the established cell line at the DNA, transcript, and protein levels by PCR, RT-PCR, and Western blotting, respectively.
Results: pLEX-LAMP2b-GRP78 was successfully developed. Co-transfection resulted in the expression of GFP by HEK293T in the control group 48 hours following transfection. The MOI of 60 was selected as 10% of cells were GFP+ 72 hours following transduction. Following puromycin selection, the presence of the integrated scFv DNA and transcript was confirmed. Moreover, Western blotting results confirmed the presence of the His-tagged scFv in the established cell line.
Conclusions: HEK293T cells can be engineered for the production of targeted exosomes which could be applied for therapeutic purposes. Moreover, scFvs are potent targeting domains that could be leveraged for the development of targeted exosomes.

Keywords

Main Subjects

References

1.‎ Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and ‎methods for exosome isolation and analysis. Cells, 2019;8 (7):727.‎ https://doi.org/10.3390/cells8070727
‎2.‎ Liang Y, Xu X, Li X, Xiong J, Li B, Duan L, Wang D, Xia J. Chondrocyte-targeted microRNA delivery ‎by engineered exosomes toward a cell-free osteoarthritis therapy. ACS applied materials & interfaces, ‎‎2020;12 (33):36938-36947.‎ https://doi.org/10.1021/acsami.0c10458
‎3.‎ Fakhoury M. Drug delivery approaches for the treatment of glioblastoma multiforme. Artificial cells, ‎nanomedicine, and biotechnology, 2016;44 (6):1365-1373.‎ https://doi.org/10.3109/21691401.2015.1052467
‎4.‎ Yuana Y, Sturk A, Nieuwland R. Extracellular vesicles in physiological and pathological conditions. ‎Blood reviews, 2013;27 (1):31-39.‎ https://doi.org/10.1016/j.blre.2012.12.002
‎5.‎ Elliott RO, He M. Unlocking the power of exosomes for crossing biological barriers in drug delivery. ‎Pharmaceutics, 2021;13 (1):122.‎ https://doi.org/10.3390/pharmaceutics13010122
‎6.‎ Wang J, Chen D, Ho EA. Challenges in the development and establishment of exosome-based drug ‎delivery systems. Journal of Controlled Release, 2021;329:894-906.‎ https://doi.org/10.1016/j.jconrel.2020.10.020
‎7.‎ Mentkowski KI, Lang JK. Exosomes engineered to express a cardiomyocyte binding peptide ‎demonstrate improved cardiac retention in vivo. Scientific reports, 2019;9 (1):1-13.‎ https://doi.org/10.1038/s41598-019-46407-1
‎8.‎ Rai R, Kennedy AL, Isingizwe ZR, Javadian P, Benbrook DM. Similarities and differences of Hsp70, ‎hsc70, Grp78 and mortalin as cancer biomarkers and drug targets. Cells, 2021;10 (11):2996.‎ https://doi.org/10.3390/cells10112996
‎9.‎ Shen J, Chen X, Hendershot L, Prywes R. ER stress regulation of ATF6 localization by dissociation of ‎BiP/GRP78 binding and unmasking of Golgi localization signals. Developmental cell, 2002;3 (1):99-‎‎111.‎ https://doi.org/10.1016/S1534-5807(02)00203-4
‎10.‎ Chen L, Zheng H, Yu X, Liu L, Li H, Zhu H, Zhang Z, Lei P, Shen G. Tumor-secreted GRP78 promotes ‎the establishment of a pre-metastatic niche in the liver microenvironment. Frontiers in Immunology, ‎‎2020;11:2544.‎ https://doi.org/10.3389/fimmu.2020.584458
‎11.‎ Shabani S, Moghadam MF, Gargari SLM. Isolation and characterization of a novel GRP78-specific ‎single-chain variable fragment (scFv) using ribosome display method. Medical Oncology, 2021;38 ‎‎(9):1-15.‎ https://doi.org/10.1007/s12032-021-01561-3
‎12.‎ Lee HK, Xiang C, Cazacu S, Finniss S, Kazimirsky G, Lemke N, Lehman NL, Rempel SA, Mikkelsen ‎T, Brodie C. GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and ‎apoptosis. Neuro-oncology, 2008;10 (3):236-243.‎ https://doi.org/10.1215/15228517-2008-006
‎13.‎ Limoni SK, Moghadam MF, Moazzeni SM, Gomari H, Salimi F. Engineered exosomes for targeted ‎transfer of siRNA to HER2 positive breast cancer cells. Applied biochemistry and biotechnology, ‎‎2019;187 (1):352-364.‎ https://doi.org/10.1007/s12010-018-2813-4
‎14.‎ Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier Drug Delivery Systems: ‎Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence. ‎Pharmaceutics, 2022;14 (4).‎ https://doi.org/10.3390/pharmaceutics14040883
‎15.‎ Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and ‎other extracellular vesicles. Annu Rev Cell Dev Biol, 2014;30:255-289.‎ https://doi.org/10.1146/annurev-cellbio-101512-122326
‎16.‎ Jiang XC, Gao JQ. Exosomes as novel bio-carriers for gene and drug delivery. Int J Pharm, 2017;521 ‎‎(1-2):167-175.‎ https://doi.org/10.1016/j.ijpharm.2017.02.038
‎17.‎ Pishavar E, Yazdian-Robati R, Abnous K, Hashemi M, Ebrahimian M, Feizpour R, Salmasi Z, Taghdisi ‎SM. Aptamer-functionalized mesenchymal stem cells-derived exosomes for targeted delivery of ‎SN38 to colon cancer cells. Iran J Basic Med Sci, 2023;26 (4):388-394.‎
‎18.‎ Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics, 2021;11 ‎‎(7):3183-3195.‎ https://doi.org/10.7150/thno.52570
‎19.‎ Zou X, Yuan M, Zhang T, Wei H, Xu S, Jiang N, Zheng N, Wu Z. Extracellular vesicles expressing a ‎single-chain variable fragment of an HIV-1 specific antibody selectively target Env(+) tissues. ‎Theranostics, 2019;9 (19):5657-5671.‎ https://doi.org/10.7150/thno.33925
‎20.‎ Xu H, Liao C, Liang S, Ye BC. A Novel Peptide-Equipped Exosomes Platform for Delivery of ‎Antisense Oligonucleotides. ACS Appl Mater Interfaces, 2021;13 (9):10760-10767.‎ https://doi.org/10.1021/acsami.1c00016
‎21.‎ Shi X, Cheng Q, Hou T, Han M, Smbatyan G, Lang JE, Epstein AL, Lenz H-J, Zhang Y. Genetically ‎Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. Molecular ‎Therapy, 2020;28 (2):536-547.‎ https://doi.org/10.1016/j.ymthe.2019.11.020
‎22.‎ Munro S, Pelham HR. An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated ‎protein and immunoglobulin heavy chain binding protein. Cell, 1986;46 (2):291-300.‎ https://doi.org/10.1016/0092-8674(86)90746-4
‎23.‎ Lee AS. Mammalian stress response: induction of the glucose-regulated protein family. Curr Opin ‎Cell Biol, 1992;4 (2):267-273.‎ https://doi.org/10.1016/0955-0674(92)90042-B
‎24.‎ Lu G, Luo H, Zhu X. Targeting the GRP78 Pathway for Cancer Therapy. Frontiers in Medicine, ‎‎2020;7.‎ https://doi.org/10.3389/fmed.2020.00351
‎25.‎ Lee HK, Xiang C, Cazacu S, Finniss S, Kazimirsky G, Lemke N, Lehman NL, Rempel SA, Mikkelsen ‎T, Brodie C. GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and ‎apoptosis. Neuro Oncol, 2008;10 (3):236-243.‎ https://doi.org/10.1215/15228517-2008-006
‎26.‎ Shabani S, Moghadam MF, Gargari SLM. Isolation and characterization of a novel GRP78-specific ‎single-chain variable fragment (scFv) using ribosome display method. Medical Oncology, 2021;38 ‎‎(9):115.‎ https://doi.org/10.1007/s12032-021-01561-3
‎27.‎ Satheeshkumar PK. Expression of Single Chain Variable Fragment (scFv) Molecules in Plants: A ‎Comprehensive Update. Molecular Biotechnology, 2020;62 (3):151-167.‎ https://doi.org/10.1007/s12033-020-00241-3
‎28.‎ Longatti A, Schindler C, Collinson A, Jenkinson L, Matthews C, Fitzpatrick L, Blundy M, Minter R, ‎Vaughan T, Shaw M, Tigue N. High affinity single-chain variable fragments are specific and versatile ‎targeting motifs for extracellular vesicles. Nanoscale, 2018;10 (29):14230-14244.‎ https://doi.org/10.1039/C8NR03970D
‎29.‎ Lu G, Luo H, Zhu X. Targeting the GRP78 Pathway for Cancer Therapy. Front Med (Lausanne), ‎‎2020;7:351.‎ https://doi.org/10.3389/fmed.2020.00351
Nanomedicine Research Journal
Volume 9, Issue 1
March 2024
Pages 52-60

Files

Share

How to cite

Statistics